|1.||Bekiari, Eleni: 1 article (01/2013)|
|2.||Vetsiou, Evaggelia: 1 article (01/2013)|
|3.||Mainou, Maria: 1 article (01/2013)|
|4.||Tsapas, Apostolos: 1 article (01/2013)|
|5.||Vlachaki, Efthymia: 1 article (01/2013)|
|6.||Tang, Peter H: 1 article (01/2012)|
|7.||Karakukcu, Musa: 1 article (01/2012)|
|8.||Karakukcu, Cigdem: 1 article (01/2012)|
|9.||Patiroglu, Turkan: 1 article (01/2012)|
|10.||Unal, Ekrem: 1 article (01/2012)|
|2.||Sickle Cell Anemia (Hemoglobin S Disease)
01/01/2013 - "These results are in accordance with previous studies about the use of DFRA in sickle cell disease."
01/01/2013 - "The aim of this report is to present the preliminary results of a pilot study assessing the effect of 4 years of DFRA treatment in six patients with sickle cell disease who are in need of recurrent transfusions. "
05/01/2011 - "A 18.75-year-old male with β-thalassemia major received oral DFRA therapy due to transfusional iron overload for 27 months. "
01/01/2013 - "Deferasirox (DFRA) is a novel oral chelator agent for treatment of iron overload. "
01/01/2011 - "Administration of L1 in a daily dose of at least 75 mg/kg may represent an alternative approach in treatment of mild and moderate iron overload in MDS patients who cannot be treated with deferasirox (DFRA) or deferoxamine (DFO)."